| Code | Description | Claims | Beneficiaries | Total Paid |
| T1015 |
Clinic visit/encounter, all-inclusive |
7,798 |
5,787 |
$429K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,079 |
10,592 |
$305K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,108 |
4,735 |
$70K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
512 |
470 |
$46K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,270 |
1,168 |
$25K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
513 |
477 |
$21K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,667 |
954 |
$17K |
| Q3014 |
Telehealth originating site facility fee |
1,156 |
985 |
$15K |
| 80061 |
Lipid panel |
1,263 |
1,158 |
$15K |
| 80053 |
Comprehensive metabolic panel |
1,373 |
1,248 |
$14K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,303 |
1,191 |
$11K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
268 |
260 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
608 |
490 |
$6K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
94 |
90 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
98 |
94 |
$3K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
396 |
361 |
$2K |
| 81025 |
|
762 |
643 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
235 |
219 |
$1K |
| 0011A |
|
27 |
27 |
$1K |
| 81002 |
|
449 |
388 |
$841.83 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
574 |
510 |
$778.35 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
43 |
41 |
$640.38 |
| 82947 |
|
311 |
284 |
$560.79 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
69 |
45 |
$515.80 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
89 |
80 |
$510.58 |
| 0012A |
|
12 |
12 |
$480.00 |
| 99051 |
|
181 |
165 |
$473.58 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
441 |
388 |
$365.98 |
| 81003 |
|
103 |
92 |
$240.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
34 |
14 |
$213.40 |
| 93000 |
|
13 |
12 |
$198.71 |
| 99000 |
|
95 |
77 |
$154.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
72 |
66 |
$103.74 |
| 3078F |
|
1,141 |
967 |
$0.00 |
| 3077F |
|
111 |
106 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
66 |
52 |
$0.00 |
| 3074F |
|
1,770 |
1,500 |
$0.00 |
| 3080F |
|
121 |
109 |
$0.00 |
| 3079F |
|
709 |
621 |
$0.00 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
19 |
17 |
$0.00 |
| 3075F |
|
96 |
88 |
$0.00 |